VolitionRx Limited Releases Annual Corporate Brochure and Video
AUSTIN, Texas, March 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition") today issued aCorporate Brochure
VolitionRx Limited to Present at Conferences in March 2020
AUSTIN, Texas, Mar. 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations,Scott Powell, is scheduled to present at five conferences in March 2020. During the conferences, Dr. Powell will outline Volitio...
VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update
AUSTIN, Texas, Feb. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2019. Volition management will host a conference call tomorrow,February 21, at 8:30 a.m. U.S. Easte...
VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunctio...
Volition Unveils Its Epigenetic Toolbox
AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that research on its Nu.Q(TM) Capture program has led to the development of a suite of novel epigenetic tools building on the breakthroughs announced last month on its assay platform...
VolitionRx Announces Filing of Registration Statements
AUSTIN, Texas, Feb. 7, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has filed registration statements on Form S-3 and Form S-8, respectively, with the Securities and Exchange Commission. The primary purpose of filing the registration statemen...
Volition Develops a New Improved Nu.Q™ Assay Format
AUSTIN, Texas, Jan. 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided an update on its Nu Q™ Clinical Assays which use a magnetic particle-based assay format. Volition has completely re-engineered its Nu.Q™ assays leading to a step-change improvement in...
VolitionRx Completes Acquisition of Octamer GmbH
AUSTIN, Texas, Jan. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the closing of the acquisition of the epigenetic reagent company Octamer GmbH ("Octamer") by its subsidiary Belgian Volition SPRL for approximately$725,000, consisting of cash and sh...
VolitionRx Limited Announces Strategic Acquisition
AUSTIN, Texas, Dec. 16, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced an agreement by its subsidiary Belgian Volition SPRL to acquire an epigenetic reagent company, Octamer GmbH ("Octamer"), for approximately$725,000 consisting of cash and shares of r...
VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
AUSTIN, Texas, Dec. 5, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it was awarded$820,000 (€740,000 Euros) and Gyros Protein Technologies AB, now part of Mesa Laboratories Inc. (NASDAQ:MLAB) was awarded$230,000 (€206,000 Euros) each in the form ...
VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia
AUSTIN, Texas, Dec. 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its latest proof of concept study. A single pre-clinical Nu.Q™ assay utilizing a basic microtiter plate platform detected 80% of newly diagnosed Non-Hodgkins Lymphoma ("N...
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update
AUSTIN, Texas, Nov 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter endedSeptember 30, 2019. Volition management will host a conference call tomorrow,November 13, at 8:30 a.m. U.S. Eastern ...
VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced it will host a conference call onWednesday, November 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2019 in addition to providin...
Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video
AUSTIN, Texas, Oct. 29, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the confirmation of a further$500,000 non-dilutive funding in the form of a loan from the Texas A&M SOFINEX funding agency of the Walloon Region to support the development of its sub...
Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC
AUSTIN, Texas, Oct. 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") announced today that it (through its subsidiaries) has executed binding agreements contemplated by the previously announced Memorandum of Understanding withTexas A&M University ("Texas A&M"), a memb...
Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical S...
Volition Appoints Dr. Phillip Barnes to Board of Directors
AUSTIN, Texas, Oct. 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the appointment of Dr.Phillip Barnes to the Company's Board of Directors as a Non-Executive Director, effectiveOctober 9, 2019. Dr. Barnes was also appointed to the Company's Audit, C...
Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
AUSTIN, Texas, Sept. 17, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.QTM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin. This breakthrough could ...
Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer
AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal health expertNathan Dewsbury as its Chief ...
VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Aug. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onTuesday, August 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2019 in addition to providing a business upd...
